The Czech Republic's health care system has been completely overhauled, replacing the nationalized system with a scheme which in theory emphasizes privatization, decentralization and competition but which actually works more pragmatically, and with only some reforms yet installed. As a result, the system is now at a crossroads, Ulrich Hoffmeyer, pharmacoeconomic scientist with Glaxo Wellcome R&D Ltd in the UK, and former senior consultant with National Economic Research Associates, told the biennual Assembly of the International Federation of Pharmaeutical Manufacturers Associations in Vienna, Austria, last month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze